Dexcom Inc is primarily active in the healthcare and medical devices industry.

The main competitors of Dexcom Inc in the market include Abbott Laboratories, Medtronic, and Tandem Diabetes Care.

Dexcom Inc is a leading medical device manufacturing company based in San Diego, California. Established in 1999, Dexcom has revolutionized diabetes management with their continuous glucose monitoring (CGM) systems. Dexcom's advanced CGM systems provide real-time glucose readings, helping diabetes patients effectively manage their condition. Over the years, the company has pioneered innovative technologies and received regulatory approvals for their life-saving products. Dexcom's commitment to improving the lives of people with diabetes has earned them a strong reputation in the medical industry. With a dedicated team of professionals, Dexcom continues to make remarkable advancements in CGM technology, offering improved accuracy and user-friendly features to enhance patients' quality of life.

Dexcom Inc has achieved several significant milestones in its corporate history. First, the company introduced the first continuous glucose monitoring (CGM) system, Dexcom STS, which revolutionized diabetes management. They further enhanced the technology with the release of Dexcom Seven Plus CGM system, offering improved accuracy and ease-of-use. Dexcom later introduced the Dexcom G4 Platinum CGM, setting new industry standards with enhanced sensor performance. Another notable milestone was the launch of Dexcom G5 Mobile CGM system, providing real-time glucose monitoring on a mobile device without the need for a separate receiver. These accomplishments reflect Dexcom Inc's commitment to improving the lives of individuals with diabetes through innovative CGM solutions.

Dexcom Inc is primarily present in several countries and regions worldwide. The company operates in the United States, Canada, Europe, including the United Kingdom, Germany, France, Italy, Spain, and Sweden. Dexcom Inc also has a significant presence in Australia and New Zealand, as well as in parts of Asia, such as Japan and South Korea. Additionally, Dexcom Inc has been expanding its reach to other global markets to provide its innovative continuous glucose monitoring systems and diabetes management solutions to a broader customer base.

Dexcom Inc is a reputable company that stands for a set of core values and a strong corporate philosophy. This company believes in providing innovative and life-changing continuous glucose monitoring (CGM) solutions for people with diabetes. Dexcom Inc consistently focuses on delivering accurate and reliable CGM technology, enhancing the lives of individuals managing this chronic condition. With a dedication to improving patient outcomes and quality of life, Dexcom Inc prioritizes patient safety, accessibility, and empowering individuals to make informed decisions about their health. Dexcom Inc's commitment to excellence and patient-centric approach has positioned it as a leader in the field of CGM technology.

Analysts currently set an average price target of 87,74 USD for the Dexcom stock (median: 86,10 USD), implying -2,2 % versus the latest price. The consensus is based on 37 analyst ratings.

Dexcom Analītiķu cenu mērķi 2026

37 analysts currently rate the Dexcom stock: 31 recommend buying, 5 holding and 1 selling. For 2026, analysts expect Dexcom to generate revenue of 5,23 B USD and earnings per share of 2,60 USD.

Dexcom Analītiķu cenu mērķi 2026

Converted at the current exchange rate, the Dexcom share trades at 79,05 EUR (91,48 USD).

The Dexcom share (DXCM) is listed on 9 stock exchanges, including: NASDAQ (DXCM), XETRA (DC4.DE), Frankfurt (DC4), München (DC4.MU), Düsseldorf (DC4.DU), Hamburg (DC4.HM), London (0A4M.L), SIX (Zürich) (DC4.SW).

Dexcom Inc. is an innovative company in the medical technology industry, specializing in the production of continuous glucose monitoring (CGM) systems for diabetes patients. Dexcom Inc. was founded in 1999 and is headquartered in San Diego, California. Dexcom's core business is the production of CGM systems. These systems allow diabetics to continuously monitor their blood sugar levels without having to regularly take blood samples. Dexcom's CGM systems use tiny sensors that are implanted under the skin to extract glucose levels from tissue. This data is transmitted to a wearable receiver or smartphone, allowing real-time monitoring of glucose levels. Dexcom's CGM systems have been developed for people with type 1 diabetes, type 2 diabetes, and gestational diabetes. In addition to the sensors, Dexcom also offers wearable receivers that allow monitoring of glucose levels at any time and anywhere. Dexcom's systems are FDA certified and have the CE Mark, indicating that they comply with strict safety and efficacy requirements. In addition to its core activity in CGM manufacturing, Dexcom also offers a range of support services for diabetes patients. These include training programs to facilitate the use of CGM systems and a customer support team available 24/7. Furthermore, the company recently entered into a partnership with Apple, allowing the Dexcom app to be downloaded on the Apple Watch, making it even easier to keep track of glucose levels. This collaboration is another step for Dexcom in improving technology and making the use of CGM systems more user-friendly. In terms of its business model, Dexcom earns money through the sale of CGM systems and accessories, as well as by providing support services. The company has an extensive distribution network and is also highly active internationally. Overall, the innovative company Dexcom Inc. has revolutionized the diabetes market with its continuous glucose monitoring. Dexcom Inc. has proven itself as a competent and trustworthy partner for diabetes patients and will continue to make a significant contribution to combating this disease.

gaidāmā apgrozījums Dexcom ir 5,23 B USD. Šis skaitlis ir balstīts uz pašreizējiem finanšu datiem un atspoguļo uzņēmuma biznesa sniegumu.

gaidāmā peļņa Dexcom ir 1,04 B USD. Neto peļņa atspoguļo uzņēmuma rentabilitāti pēc visu izdevumu atskaitīšanas.

Dexcom cenas un peļņas rādītājs (P/E) pašlaik ir 35,14. P/E rādītājs salīdzina pašreizējo akcijas cenu ar peļņu uz akciju un palīdz ieguldītājiem novērtēt Dexcom akcijas vērtību.

Dexcom cenas un apgrozījuma rādītājs (P/S) pašlaik ir 6,98. P/S rādītājs salīdzina tirgus kapitalizāciju ar gada apgrozījumu un kalpo kā Dexcom akcijas vērtības mērs.

Dexcom Eulerpool kvalitātes rādītājs ir 7/10.

Dexcom ISIN ir US2521311074. ISIN (International Securities Identification Number) ir pasaulē unikāls vērtspapīru identifikators.

Dexcom WKN ir A0D9T1. WKN (Wertpapierkennnummer) ir sešciparu vācu vērtspapīru identifikācijas numurs.

Dexcom tikeris ir DXCM. Tikeris tiek izmantots Dexcom akciju tirdzniecībai biržā.

Dexcom pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Dexcom tiek piešķirts nozarei "Veselība".

Dexcom dividendes tiek izmaksātas USD.